Exelixis (EXEL) Stock Forecast & Price Target

Exelixis is viewed favorably because its core cabozantinib franchise continues to generate durable revenue in RCC and NET, with CABINET subgroup data showing meaningful PFS benefit in both non-functional and functional NET and management describing Cabo as the leading oral small-molecule option in 2L+ NET. The company also retains upside from zanzalintinib, as STELLAR-303 showed a 15.9-month versus 12.7-month median OS trend in the NLM subgroup with a 0.83 hazard ratio, while the broader analysis and earlier published trial results support a credible path to regulatory approval despite the PDUFA delay. Beyond the pipeline, Exelixis is strengthened by strong cash generation, about $2.6B in buybacks since March 2023, and an additional $750M repurchase authorization through 2027, which reinforces capital returns and downside support.

Exelixis is viewed negatively because its lead franchise, Cabometyx, faces erosion from payer pushback, pricing pressure, and eventual generic competition in the 2030s, while the company’s future top line remains heavily dependent on maintaining cabozantinib’s share. The outlook is further weakened by uncertainty around zanzalintinib, where limited differentiation versus generic cabo could fragment the market and cap 1L and 2L opportunities to below $500M, especially if clinical data fail to look substantially better. With blockbuster status today but meaningful developmental, regulatory, and competitive risk ahead, the firm’s valuation framework already reflects a fragile lifecycle plan and a long-duration path to prove the pipeline, including a primary completion expected in 2032.